Telmisartan and esculetin combination ameliorates type 2 diabetic cardiomyopathy by reversal of H3, H2A, and H2B histone modifications.

about

Telmisartan and esculetin combination ameliorates type 2 diabetic cardiomyopathy by reversal of H3, H2A, and H2B histone modifications.

Item

http://www.wikidata.org/entity/Q51743274

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Telmisartan and esculetin comb ...... and H2B histone modifications.

@en

Telmisartan and esculetin comb ...... and H2B histone modifications.

@nl

type

Item

label

Telmisartan and esculetin comb ...... and H2B histone modifications.

@en

Telmisartan and esculetin comb ...... and H2B histone modifications.

@nl

prefLabel

Telmisartan and esculetin comb ...... and H2B histone modifications.

@en

Telmisartan and esculetin comb ...... and H2B histone modifications.

@nl

P1476

Telmisartan and esculetin comb ...... and H2B histone modifications

@en

P2093

Almesh Kadakol

http://www.w3.org/2001/XMLSchema#string

Anil Bhanudas Gaikwad

http://www.w3.org/2001/XMLSchema#string

Anuradha Pandey

http://www.w3.org/2001/XMLSchema#string

Santosh Kumar Goru

http://www.w3.org/2001/XMLSchema#string

P2860

Angiotensin II receptor blocker telmisartan attenuates aortic stiffening and remodelling in STZ-diabetic rats.

Renal failure increases cardiac histone h3 acetylation, dimethylation, and phosphorylation and the induction of cardiomyopathy-related genes in type 2 diabetes.

Mechanisms of disease:Molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes.

Cannabinoid 1 receptor promotes cardiac dysfunction, oxidative stress, inflammation, and fibrosis in diabetic cardiomyopathy

Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes.

New player on an old field; the keap1/Nrf2 pathway as a target for treatment of type 2 diabetes and metabolic syndrome.

Renin-angiotensin system and cardiovascular risk.

Does renin angiotensin system blockade deserve preferred status over other anti-hypertensive medications for the treatment of people with diabetes?

Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease

Epigenetic changes in diabetes.

P304

348-356

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4103/IJP.IJP_710_16

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Vajir Malek

P577

2017-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29515275

http://www.w3.org/2001/XMLSchema#string

P932

5830845

http://www.w3.org/2001/XMLSchema#string